Recombinant Polistes lanio Tachykinin-like peptide-I

What are the primary structural features of Polistes lanio tachykinin-like peptides?

Polistes lanio venom contains two identified tachykinin-like peptides with the sequences QPPTPPEHRFPGLM and ASEPTALGLPRIFPGLM. These peptides share sequence similarities with the C-terminal region of tachykinin-like peptides found in other venomous animals such as the Phoneutria nigriventer spider, as well as tachykinins in vertebrates . The characteristic feature of these peptides is their C-terminal sequence motif containing FPGLM, which resembles the FXGLMamide motif found in vertebrate tachykinins like Substance P (RPKPQQFFGLMamide) . This structural similarity suggests evolutionary conservation of functional domains across diverse animal taxa.

How do P. lanio tachykinin-like peptides differ from canonical vertebrate tachykinins?

While P. lanio tachykinin-like peptides share C-terminal sequence similarities with vertebrate tachykinins, they differ in several important ways:

• Vertebrate tachykinins (like Substance P) are characterized by an FXGLMamide carboxy terminus, while P. lanio peptides contain FPGLM without confirmed C-terminal amidation in their native form .

• The N-terminal regions of P. lanio tachykinin-like peptides have unique sequences not found in vertebrate tachykinins.

• Vertebrate tachykinins act on three receptor subtypes (NK1R, NK2R, and NK3R), while the receptor selectivity of P. lanio peptides has not been fully characterized, though they appear to indirectly activate NK1 receptors .

• Vertebrate tachykinins are encoded by genes (Tac1, Tac3, Tac4) that arose through genome duplications in the vertebrate lineage, whereas arthropod tachykinin-related peptides have independent evolutionary origins .

What is the current nomenclature system for tachykinin-like peptides from venomous arthropods?

Tachykinin-like peptides from arthropods are typically named using a prefix indicating the species of origin followed by "TK" for tachykinin or "TKRP" for tachykinin-related peptide . The FX₁GX₂Ramides found in invertebrates are commonly designated as tachykinin-related peptides (TKRPs) to distinguish them from vertebrate tachykinins with FXGLMamide motifs . In the literature, the P. lanio tachykinin-like peptides have not yet received standardized nomenclature, but based on conventional naming patterns, they could be designated as PlanTK-I (QPPTPPEHRFPGLM) and PlanTK-II (ASEPTALGLPRIFPGLM) or PlanTKRP-I and PlanTKRP-II.

What are the recommended methods for recombinant expression of P. lanio tachykinin-like peptide-I?

For recombinant expression of P. lanio tachykinin-like peptide-I, researchers should consider the following methodological approach:

• Gene synthesis and codon optimization: Design a synthetic gene encoding the peptide sequence QPPTPPEHRFPGLM, optimized for the expression host (typically E. coli, yeast, or insect cells).

• Expression vector construction: Clone the synthetic gene into an appropriate expression vector with a fusion tag (His-tag, GST, or SUMO) to facilitate purification and enhance solubility.

• Expression system selection: For small peptides like tachykinins, bacterial expression systems (E. coli BL21(DE3) or similar strains) are often sufficient, though eukaryotic systems may better preserve post-translational modifications.

• Purification strategy: Implement a two-step purification protocol using affinity chromatography followed by reverse-phase HPLC to obtain high purity peptide.

• Tag removal: Include a specific protease cleavage site between the tag and peptide sequence for post-purification removal of the fusion partner.

• Quality control: Verify the identity and purity of the recombinant peptide using mass spectrometry, comparing the molecular weight to the theoretical mass of QPPTPPEHRFPGLM (1655.84 Da).

When working with tachykinin-like peptides, it's crucial to verify biological activity against native venom fractions to ensure proper folding and functionality of the recombinant product.

What analytical techniques are most effective for characterizing recombinant P. lanio tachykinin-like peptides?

Multiple complementary analytical techniques should be employed for comprehensive characterization:

• Mass spectrometry: LC-MS/MS analysis is essential for confirming peptide sequence, molecular weight, and potential post-translational modifications. This technique was successfully used to identify the native peptides in P. lanio venom .

• Circular dichroism (CD) spectroscopy: Useful for analyzing the secondary structure of the peptide in different solution conditions, providing insights into conformational properties.

• NMR spectroscopy: For detailed three-dimensional structural characterization, especially to determine if the peptide adopts a defined structure in solution or when interacting with receptor models.

• Receptor binding assays: Using radioligand displacement or fluorescence-based assays with NK1, NK2, and NK3 receptors to determine receptor selectivity profiles.

• Functional assays: Calcium mobilization assays in receptor-expressing cell lines to measure downstream signaling activation, complemented by tissue-based assays (e.g., smooth muscle contraction).

• Stability studies: Analyzing peptide stability under various pH conditions, in the presence of proteases, and during storage using HPLC and mass spectrometry.

• Immunoreactivity tests: Cross-reactivity studies with anti-tachykinin antibodies to confirm structural similarities with known tachykinins.

How can researchers effectively assess the purity and activity of synthesized P. lanio tachykinin-like peptide-I?

A multi-step approach is recommended for quality assessment:

Purity assessment:

• Analytical HPLC with multiple solvent systems to detect impurities

• Capillary electrophoresis for charge-based separation of contaminants

• Mass spectrometry to identify any truncated forms or synthesis byproducts

• Amino acid analysis to confirm composition

Activity assessment:

• Microvascular permeability assay: Measure Evans blue extravasation in mouse dorsal skin following intradermal injection, comparing to native venom effects as described in previous studies .

• NK receptor activation: Use cell lines expressing NK1R, NK2R, or NK3R to measure calcium mobilization or other second messenger responses.

• Sensory neuron activation: Calcium imaging in cultured dorsal root ganglion neurons to assess direct activation of sensory fibers.

• Edema formation assay: Quantify paw edema in mouse models using plethysmography, with NK receptor antagonists (e.g., SR140333) as controls .

• Mast cell degranulation: Assess the peptide's ability to directly or indirectly trigger histamine release from mast cells.

Researchers should aim for >95% purity for biological studies and include appropriate positive controls (native venom fractions) and negative controls (vehicle, scrambled peptide sequences).

What is the current understanding of the inflammatory mechanism of P. lanio tachykinin-like peptides?

P. lanio venom induces potent edema and increases vascular permeability primarily through a neurovascular mechanism involving tachykinin signaling . The current evidence suggests a multi-step process:

• Venom components, potentially including the tachykinin-like peptides, activate sensory C fibers, as evidenced by reduced inflammatory responses in capsaicin-treated rats (which depletes sensory neuropeptides) .

• This activation leads to the release of substance P from sensory neurons, which then activates tachykinin NK1 receptors.

• NK1 receptor activation triggers a cascade resulting in histamine release from dermal mast cells.

• Histamine acts on H1 receptors to increase vascular permeability and edema formation.

This mechanism is supported by the finding that an NK1 receptor antagonist (SR140333) markedly inhibited the inflammatory response to P. lanio venom, while an NK2 receptor antagonist (SR48968) was ineffective . Additionally, the histamine H1 receptor antagonist pyrilamine inhibited venom-induced edema, further confirming this pathway .

The specific contribution of each of the two identified tachykinin-like peptides (QPPTPPEHRFPGLM and ASEPTALGLPRIFPGLM) to this inflammatory cascade remains to be fully elucidated.

How do the receptor affinities of P. lanio tachykinin-like peptides compare to mammalian tachykinins?

While direct comparative receptor binding studies specifically for P. lanio tachykinin-like peptides are not detailed in the provided search results, general patterns in tachykinin receptor pharmacology provide a framework for understanding:

Mammalian tachykinin receptor selectivity:

Importantly, invertebrate tachykinin-related peptides (TKRPs) with FX₁GX₂Ramide motifs are typically inactive on vertebrate TK receptors and vice versa . This suggests that the P. lanio peptides may have evolved specifically to target host inflammatory pathways through indirect mechanisms rather than direct receptor activation.

What physiological responses have been documented for P. lanio tachykinin-like peptides beyond inflammation?

While the inflammatory responses to P. lanio venom have been well-documented (including increased microvascular permeability and neutrophil influx) , specific physiological effects attributable exclusively to the tachykinin-like peptides require further investigation. Based on the known functions of tachykinins across species, potential physiological responses may include:

• Nociception: Tachykinins are well-established pain mediators, suggesting the peptides may contribute to the pain associated with P. lanio stings.

• Smooth muscle effects: Many tachykinins cause contraction of smooth muscle in various tissues, including respiratory and gastrointestinal systems.

• Neuronal excitability: Tachykinins modulate neuronal activity in both central and peripheral nervous systems.

• Immune modulation: Beyond acute inflammation, tachykinins influence various aspects of immune function.

Interestingly, some invertebrate venoms contain tachykinin-like peptides that target the predator's or prey's nervous system. For example, in the parasitoid wasp Nasonia vitripennis, venom-derived FQGMRamide peptides act on the cockroach tachykinin receptor in central complex circuits to induce paralysis . Whether P. lanio tachykinin-like peptides serve similar functions requires further investigation.

What structure-activity relationship studies have been conducted on P. lanio tachykinin-like peptides?

Comprehensive structure-activity relationship (SAR) studies specifically for P. lanio tachykinin-like peptides are not detailed in the provided search results, representing a significant knowledge gap and research opportunity. Based on general tachykinin SAR principles, the following aspects would be valuable to investigate:

• C-terminal modifications: The C-terminal FPGLM motif likely represents the message domain critical for biological activity. Systematic alanine scanning or truncation studies would help determine essential residues.

• N-terminal modifications: The unique N-terminal sequences (QPPTPPEHR- and ASEPTALGLPRI-) likely contribute to receptor selectivity, stability, or other pharmacological properties.

• Amidation status: Determining whether C-terminal amidation affects the activity of these peptides, as amidation is critical for many bioactive peptides including canonical tachykinins.

• Conformational constraints: Introduction of structural constraints (e.g., disulfide bridges, lactam rings) to stabilize bioactive conformations could enhance potency or receptor selectivity.

• D-amino acid substitutions: Replacing L-amino acids with D-isomers at specific positions could increase resistance to proteolytic degradation and potentially alter receptor selectivity profiles.

Future SAR studies should prioritize both the ligand-binding properties (receptor affinity and selectivity) and the functional consequences (inflammatory pathway activation, sensory neuron stimulation) of structural modifications.

What are the challenges in determining the three-dimensional structure of P. lanio tachykinin-like peptides?

Determining the three-dimensional structure of small peptides like P. lanio tachykinin-like peptides presents several technical challenges:

• Conformational flexibility: Small peptides often lack stable secondary structures in solution, existing as dynamic ensembles of conformations rather than a single defined structure. This flexibility complicates structure determination by techniques like X-ray crystallography.

• Solvent-dependent conformations: Tachykinin-like peptides may adopt different conformations in different environments (aqueous solution vs. membrane-mimetic conditions vs. receptor-bound state), necessitating multiple experimental approaches.

• Aggregation tendencies: Some peptides, particularly those with amphipathic properties, tend to aggregate at the concentrations required for NMR studies, complicating spectral interpretation.

• Receptor-bound conformation: The biologically relevant conformation is often the receptor-bound state, which is challenging to capture experimentally, especially given the multiple possible receptor targets.

• Post-translational modifications: Potential modifications like C-terminal amidation can significantly impact structure and need to be accurately represented in recombinant or synthetic peptides.

Researchers should consider using a combination of circular dichroism, NMR spectroscopy in various solvent conditions (including membrane-mimetic environments), and computational modeling approaches to address these challenges.

How can researchers engineer modified versions of P. lanio tachykinin-like peptide-I with enhanced stability or selective receptor targeting?

Several strategic approaches can be employed to engineer enhanced versions of P. lanio tachykinin-like peptide-I:

For enhanced stability:

• N-terminal acetylation: Protects against aminopeptidase degradation

• C-terminal amidation: If not naturally present, may enhance stability and bioactivity

• Incorporation of D-amino acids: Particularly at known protease cleavage sites

• Cyclization: Head-to-tail cyclization or introduction of lactam bridges between side chains

• Non-natural amino acid substitutions: Using β-amino acids or N-methylated amino acids at vulnerable positions

• PEGylation: At non-critical positions to reduce proteolytic accessibility and improve pharmacokinetics

For selective receptor targeting:

• Chimeric peptides: Creating hybrids with sections from receptor-selective mammalian tachykinins like Substance P (NK1R-selective) or Neurokinin A (NK2R-selective)

• Positional scanning libraries: Systematic replacement of individual amino acids to identify positions crucial for receptor subtype selectivity

• Conformational constraints: Introducing constraints that lock the peptide in the bioactive conformation preferred by specific receptor subtypes

• Multivalent constructs: Developing dimeric or tetrameric constructs with enhanced avidity for target receptors

These modifications should be guided by comparative analysis of the P. lanio sequences with known receptor-selective tachykinins and followed by rigorous functional testing in receptor-specific assays.

How do P. lanio tachykinin-like peptides compare to similar compounds in other Hymenoptera venoms?

Tachykinin-like peptides have been identified in several Hymenoptera venoms, though comparative data specifically relating to P. lanio peptides is limited in the provided search results. Some notable comparisons include:

• In the parasitoid wasp Nasonia vitripennis, venom contains FQGMRamide-containing peptides that target the tachykinin receptor in cockroach brain circuits to induce paralysis . This represents a specialized adaptation for host manipulation rather than defensive functions.

• The sequences of P. lanio tachykinin-like peptides (QPPTPPEHRFPGLM and ASEPTALGLPRIFPGLM) show some similarities to these specialized venom peptides but appear to have evolved for different functional roles, primarily related to inducing inflammatory responses in vertebrate targets.

• Venom-derived tachykinin-like peptides often show structural deviations from the endogenous tachykinins of the same species, suggesting specialized adaptations for targeting prey or predator physiological systems rather than conspecifics.

• The presence of tachykinin-like peptides across different venomous Hymenoptera suggests convergent evolution toward utilizing this signaling pathway as an effective target for venom action, despite differences in specific amino acid sequences.

Comparative analysis across Hymenoptera venoms could provide valuable insights into the evolutionary pressures shaping venom composition and the structural determinants of target specificity.

What evolutionary insights can be gained from studying P. lanio tachykinin-like peptides?

The study of P. lanio tachykinin-like peptides offers several evolutionary insights:

• Molecular convergence: The similarity between these peptides and vertebrate tachykinins, despite their independent evolutionary origins, suggests convergent evolution toward effective targeting of conserved physiological pathways.

• Predator-prey coevolution: The peptides' ability to activate mammalian inflammatory pathways indicates adaptation specifically to defend against vertebrate predators, revealing coevolutionary dynamics between wasps and their potential predators.

• Venom diversification: The presence of two distinct tachykinin-like peptides in P. lanio venom demonstrates diversification within this peptide family, potentially reflecting fine-tuning of venom composition for specific defensive functions.

• Ancient signaling systems: Tachykinins represent an ancient neuropeptide family present throughout bilaterians , and the evolution of venom peptides targeting these conserved systems demonstrates how venomous organisms exploit fundamental physiological mechanisms that have deep evolutionary roots.

• Subfunctionalization: Comparison with related species could reveal how gene duplication events might have allowed specialization of different tachykinin-like peptides for distinct functions within the venom.

These evolutionary insights could inform broader understanding of venom evolution and the molecular mechanisms underlying predator-prey interactions.

What are the differences in biological activities between recombinant and native P. lanio tachykinin-like peptide-I?

This represents an important research question that requires empirical investigation. Based on general principles of peptide biochemistry and the limited information available, several potential differences may exist:

• Post-translational modifications: Native P. lanio tachykinin-like peptides may possess post-translational modifications (such as C-terminal amidation) that might not be present in recombinant versions unless specifically engineered. These modifications can significantly impact biological activity.

• Folding and conformation: While small linear peptides typically don't have complex tertiary structures, local conformational preferences might differ between recombinant and native peptides due to differences in synthesis and processing.

• Synergistic effects: In the native venom, tachykinin-like peptides act in concert with other venom components, potentially producing synergistic effects that would not be observed with isolated recombinant peptides.

• Stability profiles: Native peptides exist in the context of the whole venom, which may contain stabilizing factors or protective elements that extend their biological half-life compared to recombinant versions.

• Aggregation state: Differences in handling, storage, or expression systems might lead to different aggregation states between native and recombinant peptides, potentially affecting their bioavailability and activity.

To accurately assess these differences, researchers should conduct side-by-side comparisons of native (venom-extracted) and recombinant peptides using identical assay conditions and multiple functional readouts.

How can recombinant P. lanio tachykinin-like peptide-I be utilized as a tool to study neurogenic inflammation?

Recombinant P. lanio tachykinin-like peptide-I offers several valuable applications for studying neurogenic inflammation:

• Mechanistic dissection: As a tool to activate specific components of the neurogenic inflammatory pathway, the peptide could help dissect the sequence of molecular events from sensory neuron activation to increased vascular permeability.

• Receptor pharmacology: The peptide could serve as a novel ligand for characterizing tachykinin receptor pharmacology, potentially revealing receptor subtype-specific effects or unique signaling pathways not activated by canonical tachykinins.

• Species-specific differences: By testing the peptide's effects across different mammalian models, researchers could investigate species differences in neurogenic inflammatory responses, relevant to understanding the ecological function of wasp venoms.

• Development of inflammation models: The peptide could be used to establish reproducible models of acute neurogenic inflammation for testing anti-inflammatory compounds.

• Structure-function studies: By comparing the native peptide with systematically modified versions, researchers could identify structural elements critical for different aspects of neurogenic inflammation (sensory neuron activation, mast cell degranulation, vasodilation).

• Cross-talk with other inflammatory pathways: The peptide could be used to investigate interactions between neurogenic inflammation and other inflammatory mechanisms, such as those mediated by cytokines or the complement system.

What are the potential therapeutic implications of research on P. lanio tachykinin-like peptides?

Research on these peptides could have several therapeutic implications:

• Novel analgesic development: Understanding how these peptides activate pain pathways could lead to the development of new NK1 receptor antagonists or other compounds that interrupt neurogenic inflammatory signaling for pain management.

• Anti-inflammatory strategies: The peptides' mechanisms of action could reveal new targets for treating inflammatory conditions where neurogenic components play a significant role, such as asthma, inflammatory bowel disease, or certain dermatological conditions.

• Venom immunotherapy: Better characterization of venom components including tachykinin-like peptides could improve diagnostic and therapeutic approaches for Hymenoptera venom allergies.

• Drug delivery systems: Modified versions of these peptides could potentially be developed as vectors for delivering therapeutic agents to specific tissues or cells that express tachykinin receptors.

• Biomarkers: Understanding the downstream effects of these peptides could identify biomarkers useful for diagnosing or monitoring inflammatory conditions.

• Therapeutic peptide design: The structural and functional characteristics of these venom peptides could inform the design of novel therapeutic peptides with defined receptor selectivity and pharmacokinetic properties.

What are the most promising future research directions for P. lanio tachykinin-like peptides?

Several promising research directions warrant further investigation:

• Comprehensive structural characterization: Determining the three-dimensional structure of these peptides in solution and when bound to different receptor subtypes.

• Receptor selectivity profiling: Detailed characterization of their interactions with different tachykinin receptor subtypes across various species.

• Mechanism of action studies: Elucidating whether the peptides directly activate tachykinin receptors or work through indirect mechanisms, such as stimulating the release of endogenous tachykinins.

• Signaling pathway analysis: Investigating whether these peptides activate unique intracellular signaling pathways distinct from those triggered by canonical tachykinins.

• Biodistribution and pharmacokinetics: Studying how these peptides distribute in tissues and their stability in biological fluids.

• Ecological function: Investigating the role of these peptides in the wasp's defense against predators and potential prey capture.

• Comparative venomics: Analyzing related peptides across different Polistes species to understand evolutionary patterns and structure-function relationships.

• Modified peptide development: Creating modified versions with enhanced stability, receptor selectivity, or novel biological activities for research and potential therapeutic applications.

• Cross-reactivity with allergens: Investigating potential cross-reactivity between these peptides and known allergens, which could have implications for understanding and treating Hymenoptera venom allergies.

Pursuing these research directions would significantly advance our understanding of this fascinating class of venom peptides and potentially lead to valuable biomedical applications.